Counterfeit Ozempic charges reach the packaging, labels and needles
1 min read
Original editorial artwork from the Hugin archive; symbolic supply-chain illustration.
Federal prosecutors announced charges against two people over an alleged 2023–2024 distribution scheme. One made his first appearance in Tampa after extradition from Italy. The allegations concern an imitation supply chain, not a finding that every discounted medicine is counterfeit.
A counterfeit medicine can come with counterfeit evidence of authenticity.
Federal prosecutors in Florida announced September 29 that Swapnadip Roy and Vicky Ramancha face charges over an alleged counterfeit Ozempic distribution scheme. Roy made his initial appearance in Tampa that day after extradition from Italy.
What is alleged
The Justice Department says the alleged July 2023–April 2024 scheme obtained counterfeit products from unauthorized sources in China and sold them to U.S. distributors at steep discounts. The imitation extended to packaging, inserts, pen labels and needles. Prosecutors allege distribution continued after FDA's December 2023 seizure and warning.
These are charges, not convictions. Both defendants are presumed innocent. The release does not establish a patient injury attributable to these defendants.
What patients can check
FDA's separate counterfeit alert carries photographs and lot-specific instructions. It advises obtaining Ozempic with a valid prescription through state-licensed pharmacies. Later warnings on that page should not be treated as evidence about this prosecution.
